Whitehawk Therapeutics, Inc.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.1M
- Net income
- -$20.6M
- Total assets
- $150.8M
- Market cap
- $205.2M
- Gross margin
- 89.4%
- Operating margin
- -1601.1%
- Net margin
- -288.3%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $7.1M
- Cost of revenue
- $760.0K
- Gross profit
- $6.4M
- Operating expenses
- $120.8M
- Operating income
- -$114.4M
- Income tax
- $0
- Net income
- -$20.6M
- EPS (basic)
- $-0.33
- EPS (diluted)
- $-0.33
Balance sheet
- Total assets
- $150.8M
- Current assets
- $149.0M
- Total liabilities
- $14.5M
- Current liabilities
- $14.5M
- Shareholders’ equity
- $136.3M
Cash flow
- Operating cash flow
- -$97.4M
- Investing cash flow
- $11.9M
- Financing cash flow
- $94.4M
- Net cash flow
- $8.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $205.2M
- EPS (diluted)
- $-0.33
- Shares outstanding
- 51.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 27, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $20.6M in FY2025.
- Gross margin of 89.4%, net margin -288.3%.
- Trading 21% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Whitehawk Therapeutics, Inc..
